

Curriculum vitae

Prof. Dr. Michael Kreuter, M.D.

Head, Center for interstitial and rare lung diseases, Thoraxklinik Heidelberg, Röntgenstr. 1, 69126 Heidelberg, University of Heidelberg, Germany

Director, Department of Pneumology, Thoraxklinik Ludwigsburg, Interdisciplinary Lung Center, Posipolistr. 4, 71640 Ludwigsburg, Germany

Education and professional experience

1999	Philipps-University Marburg, Germany Graduation in Medicine
1999-2010	Residency: Dep. of Internal Medicine A, University of Muenster, Germany Children's Hospital Boston (research), USA Departments of Pneumology and of Thoracic Oncology, Thoraxklinik, University of Heidelberg, Germany
Since 2010	Head of the center for interstitial and rare lung diseases and consultant of the Dep. of Pneumology, Thoraxklinik, University of Heidelberg
Since 2013	Principal Investigator, German Center for Lung Research
Since 2015	Professor of Medicine (Apl), Karl-Ruprechts-University of Heidelberg, Germany

Degrees

2010	Specialist in Pneumology
2008	Specialist in Hematology and Oncology
2007	Specialist in Internal Medicine


Scientific activities

- Head of the steering committee of the German ILD registry "EXCITING" within the DZL
- Steering committee member of the German ILD registries "INSIGHTS-IPF" & "INSIGHTS-ILD"
- Steering committee member of clinical phase 2 & 3 trials in ILD
- Local PI of > 20 clinical trials on interstitial lung diseases
- Associate Editor of European Respiratory Review
- Awards: 1) Science award Lungenfibrose e.V., 2015; 2) Teaching award, Lungenfibrose e.V. 2017 3) Scientific award of Rosemarie-Germscheid-Stiftung, Deutsche Rheuma Liga 2020 4) Educational award, European Respiratory Society, 2021

Educational and other activities

- Scientific head and organizer of the European Respiratory Society (ERS) schools on Interstitial Lung Diseases since 2013
- Scientific head and organizer of the annual German Symposia on "Rare lung disease in focus", since 2013
- Member of the ERS (Assembly secretary of the ILD assembly), DGP (vice head of the group on rare lung diseases), WATL, Principle Investigator of the German center for Lung Research
- Member of the European Reference Network for rare diseases, deputy chair of ERN-ILD and ERN-LUNG education
- Chief medical advisor for the German patient support group "Lungenfibrose e.V."

Heidelberg, 22nd JUL 2022



Prof. Dr. Michael Kreuter

Top-10 selected Publications

126 peer reviewed original articles (68 first-/senior-authorships; 84 Co-authorships), current h-Index 52 (google-scholar), 7 national and international guidelines, 11 Position Papers, 86 Reviews, 3 Book editorships, 19 book chapters

Marijic P, et al. (2022). Effects of influenza vaccination in patients with interstitial lung diseases: an epidemiological claims data analysis. *Annals ATS*, in press

Kreuter M, et al. (2021). Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. *Am J Res Crit Care Med*, 204(1):74-81.

Behr, J et al. (2020). Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry, *Eur Res J*, 56:1902279

Trapnell et al, (2020). Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis, *New Engl J Med*, 383(17):1635-1644

Kreuter M, et al. (2020). Acute exacerbation of idiopathic pulmonary fibrosis: International survey and call for harmonisation. *Eur Res J*, 55: 1901760,

Kreuter M, et al (2019). Concomitant Medications and Clinical Outcomes in Idiopathic Pulmonary Fibrosis. *Eur Res J*, 53:1801587

Crestani B, et al. (2019). Long-term treatment with nintedanib in patients with idiopathic pulmonary fibrosis: results from INPULSIS-ON. *Lancet Respir Med*, 7: 60-68

Kreuter M, et al. (2019). Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. *Chest*, 156: 706-714

Kreuter M, et al (2016). Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. *Lancet Respir Med*, 4: 381-389

Kreuter M, et al. (2016). Unfavourable effects of medically indicated oral anticoagulants on survival in IPF. *Eur Res J*, 47: 1776-1784